Lactate-Histone Feedback Loop Drives Fatty Liver Disease Progression
A newly discovered lactate-H4K16la-PDK4 feedback loop accelerates metabolic fatty liver disease — and blocking it may offer a therapeutic path.
Summary
Researchers have uncovered a self-reinforcing cycle that drives metabolic-associated fatty liver disease (MAFLD), one of the world's fastest-growing liver conditions. When liver cells accumulate excess fat, they produce more lactate. That lactate chemically modifies a histone protein (H4K16) in a process called lactylation, which in turn switches on a gene called PDK4. PDK4 then amplifies glycolysis, producing even more lactate — creating a vicious feedback loop. The team demonstrated this cycle in mouse models of fatty liver disease and confirmed elevated H4K16 lactylation in human liver tissue. Crucially, blocking PDK4 genetically or with a drug called dichloroacetic acid reduced fat buildup, inflammation, and liver injury. The findings identify PDK4 as a promising drug target for MAFLD and its more severe form, MASH.
Detailed Summary
Metabolic-associated fatty liver disease (MAFLD) affects hundreds of millions of people worldwide and can progress to life-threatening cirrhosis and liver cancer. Despite its prevalence, the molecular mechanisms driving its escalation remain poorly understood, limiting treatment options. This study sheds new light on how the liver's own metabolic byproducts fuel disease progression through an epigenetic feedback loop.
Researchers at Shandong Provincial Hospital used two mouse models of MAFLD — a high-fat diet and a choline-deficient high-fat diet — alongside cultured hepatocytes exposed to oleic and palmitic acids. Using cutting-edge epigenomic tools including CUT&Tag and RNA sequencing, they mapped how histone lactylation patterns shift during disease and identified which genes are activated as a result.
The central finding is a self-amplifying axis: excess lactate produced during fatty liver disease modifies histone H4 at lysine 16 (H4K16la), an epigenetic mark that directly activates transcription of PDK4, a key regulator of glucose metabolism. PDK4 activity then boosts glycolysis, generating more lactate — closing the feedback loop. H4K16la levels were elevated in both mouse and human MASH liver tissue and correlated strongly with steatosis, inflammation, and fibrosis severity.
Breaking this cycle proved effective. Introducing an H4K16R mutation (which cannot be lactylated), knocking down PDK4, or administering dichloroacetic acid (DCA, a PDK4 inhibitor) all reduced lactate accumulation, lipid buildup, and liver injury in experimental models. This convergence of genetic and pharmacologic evidence strengthens the causal case for the lactate-H4K16la-PDK4 axis.
For clinicians and researchers in metabolic health and longevity, these findings reframe MAFLD progression as an epigenetically driven metabolic reprogramming event. PDK4 inhibition emerges as a concrete therapeutic target, and histone lactylation may serve as a novel biomarker of disease severity. Limitations include reliance on mouse models and cell culture, with human therapeutic validation still required.
Key Findings
- H4K16 histone lactylation is elevated in both mouse models and human MASH liver tissue, correlating with disease severity.
- H4K16la directly activates PDK4 transcription, creating a lactate-driven feedback loop that worsens MAFLD.
- Blocking PDK4 genetically or with dichloroacetic acid (DCA) reduced lipid accumulation, inflammation, and liver injury.
- The lactate-H4K16la-PDK4 axis represents a novel epigenetic mechanism of metabolic reprogramming in fatty liver disease.
- PDK4 inhibition is identified as a promising therapeutic strategy for MAFLD and MASH.
Methodology
The study used C57BL/6 mice fed high-fat or choline-deficient high-fat diets, plus in vitro hepatocyte models treated with oleic and palmitic acids. CUT&Tag sequencing and RNA-seq identified H4K16la target genes, while H4K16R mutation, PDK4 knockdown, and DCA treatment were used to validate the proposed mechanism in both cell and animal models.
Study Limitations
The summary is based on the abstract only, as the full text was not available. All mechanistic experiments were conducted in mouse models and cultured cells; direct human therapeutic evidence is lacking. Dichloroacetic acid has known toxicity concerns at higher doses, so clinical translation will require careful safety profiling.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: